Rochester, MNNCT06356272Now EnrollingIRB Ready

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Clinical Trial in Rochester, MN

Access cutting-edge clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8 treatment through this clinical trial at a research site in Rochester. Study-provided care at no cost to qualified participants.

Sponsored by Mayo Clinic

Quick Self-Assessment

See if you qualify for this Rochester location

Preparing your pre-screening questions…

Expert Care in Rochester

Access clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8 specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8 treatment provided free

Apply for This Rochester Location

Check if you qualify for this clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8 clinical trial in Rochester, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Rochester

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Rochester site if eligible
  4. 4Begin participation

About This Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Study in Rochester

The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent.

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Age ≥ 18 years
Able to provide written consent
Groups 1-3:
Must undergo p16 staining on biopsy for enrollment
Patients with \< 70% of tumor cells positive for p16 will be considered p16 negative
Must undergo HPV16 family in situ hybridization (ISH) and/or RNA on biopsy or surgical specimen, unless amount of tissue is too small to have conclusive HPV ISH testing done on it
Willingness and intent to return in person to enrolling institution for follow-up (during the Active Monitoring Phase of the study) for at least 2 of the standard follow-up time points for a total of 3 time-points including pre-treatment. A participant who does not return in person to Mayo Clinic Rochester for every standard of care post-treatment follow up will not be considered deviating from the protocol
Clinical suspicion or histopathologic diagnosis of head and neck cancer or neoplasm
Primary salivary neoplasm
Primary thyroid neoplasm
Primary head and neck neoplasm
Multi-cancer early detection (MCED) testing concerning for cancer
Patient has given permission to give his/her tumor/tissue/blood/saliva sample for research testing
Ability to complete questionnaire(s) by themselves or with assistance
Primary language: English, Spanish, Arabic

Exclusion Criteria

Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.
Groups 1-3:
Other active malignancy ≤ 5 years prior to registration
EXCEPTIONS: Non-melanotic skin cancer, non-metastatic thyroid cancer, non-metastatic prostate cancer, carcinoma-in-situ of the cervix, HPV+ oropharyngeal squamous cell carcinoma (SCC) (which can be enrolled in group 3)
NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
History of any head and neck malignancy, other than the tumor for which they are being treated
Group 4, Cohort A, B, C:
Other active malignancy ≤ 5 years prior to registration
EXCEPTIONS: Non-metastatic prostate cancer, carcinoma-in-situ of the cervix, non metastatic cutaneous basal cell carcinoma
NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment for their cancer
History of any head and neck malignancy, other than the present neoplasm
Note these are clarifications of inclusion into Group 4, Cohorts D and E:
Presence of other active malignancy or recurrent head and neck neoplasms are allowed in this arm
Receipt of cancer specific therapy for other malignancy is allowed in this arm

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rochester?

Yes, this clinical trial (NCT06356272) has an active research site in Rochester, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Treatment Options in Rochester, MN

If you're searching for clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8 treatment options in Rochester, MN, this clinical trial (NCT06356272) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8 clinical trials near you to find additional studies recruiting in your area.

More Head and Neck Cancer Trials in Rochester, MN

See all head and neck cancer clinical trials recruiting in Rochester — not just this study.

Browse Head and Neck Cancer Trials in Rochester →

Browse More Trials by Condition

Head and Neck Cancer TrialsPulmonary Hypertension TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Rochester?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Rochester, MN